Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 MK-5684 vs alternate abiraterone or enzalutamide in mCRPC after prior next‑generation hormonal agent
jRCT2031240030Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Merck & Co. Primary endpoints: Radiographic Progression-Free Survival and Overall Survival. Started May 2024; status: recruiting.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031240030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240030.